Orris

Cannabis induced MI overview

Reading File
Finding Sources
Searching PubMed

cannabis marijuana myocardial infarction

Searching the Web

cannabis induced myocardial infarction mechanism pathophysiology 2024 2025

Reading File
Reading Article
Reading Article
Reading File
Finding Sources
Reading Article
Reading File
Finding Sources
I now have sufficient information for a comprehensive answer. Here is a full overview:

Cannabis-Induced Myocardial Infarction

Epidemiology & Background

Cannabis (marijuana) is the most widely used illicit substance worldwide - in the US alone, ~48 million people used it at least once in 2019. As legalization expands, cardiovascular complications are attracting increasing attention. Cannabis-induced MI disproportionately affects young males (<45 years) with no or minimal traditional cardiovascular risk factors, often presenting with their first-ever MI.
The ACC (2025) published a large retrospective study of 4.6 million people alongside a meta-analysis of 12 studies at ACC.25, both confirming substantially elevated MI risk in cannabis users.

Mechanisms

Cannabis contains delta-9-tetrahydrocannabinol (THC) as its primary psychoactive compound, acting mainly on CB1 receptors (found in the heart, vasculature, and CNS). Several converging pathways explain MI risk:

1. Sympathetic Activation and Increased Myocardial Oxygen Demand

THC acutely increases sympathetic activity while decreasing parasympathetic activity. This causes:
  • Tachycardia (heart rate increase of 20-100%)
  • Supine hypertension
  • Increased cardiac output and myocardial work
  • Systemic catecholamine release
The net effect is a sharp rise in myocardial oxygen demand without a compensatory increase in coronary blood flow - producing supply-demand mismatch and ischemia. - Murray & Nadel's Textbook of Respiratory Medicine

2. Coronary Vasospasm

Many published cases of cannabis-associated MI show normal or near-normal coronary angiography, pointing to vasospasm (Prinzmetal-like) as a dominant mechanism. THC-mediated catecholamine release constricts coronary arteries, and endothelial dysfunction further promotes vasospasm. Microvascular spasm has also been implicated.

3. Prothrombotic Effects

THC activates platelets and causes endothelial dysfunction, tipping hemostasis toward thrombosis. In the setting of vasospasm and increased heart rate, even a small thrombus on a non-obstructive plaque can cause MI (type 2 MI mechanism).

4. Carbon Monoxide (Smoking Route)

Cannabis smoke induces a nearly 5-fold increase in carboxyhemoglobin and a 3-fold increase in tar compared to tobacco. Elevated carboxyhemoglobin reduces oxygen-carrying capacity, worsening supply-demand mismatch. This is specific to the smoked route.

5. Anxiety/Psychosis-Mediated Stress

Extreme anxiety, hallucinations, and psychosis from THC can independently trigger catecholamine surges sufficient to precipitate vasospasm or plaque rupture.

Route of Administration Matters

A 2024 systematic review by van Amsterdam & van den Brink (PMID 39337107) found:
  • Cannabis smoking - independently associated with MI even after adjustment for concurrent tobacco use (aOR 1.03-5.24; particularly high in younger patients). In never-tobacco-smokers, frequent cannabis smoking had an aOR of 1.88 for MI.
  • Vaping and edibles - NOT significantly associated with increased MI risk in current evidence (aOR 1.00-1.31, ns), likely because the absence of combustion prevents exposure to carbon monoxide and other toxins.

Magnitude of Risk

From a 2025 systematic review and meta-analysis (Storck et al., PMID 40527600, Heart; 24 studies, real-world data):
OutcomeRisk Ratio (95% CI)
Acute coronary syndrome (incl. MI)1.29 (1.05-1.59)
Stroke1.20 (1.13-1.26)
Cardiovascular death2.10 (1.29-3.42)
Risk is greater in patients with underlying cardiovascular disease. Daily use amplifies risk proportionally.

Clinical Presentation

  • Typically young male (<45 years), often no prior cardiac history
  • Temporal association: MI usually within 1-4 hours of cannabis use (the peak cardiovascular risk window)
  • Chest pain, diaphoresis, dyspnea - indistinguishable from conventional MI
  • ECG: ST-elevation or non-ST-elevation MI
  • Angiography: frequently shows normal coronaries or non-obstructive CAD (suggesting vasospasm > plaque rupture), though obstructive disease and thrombus-in-situ are also reported
  • Urine/serum toxicology positive for THC

Risk Factors for Severe Events

  • Pre-existing cardiovascular disease - cardiovascular toxicity substantially amplified
  • High-potency THC products (concentrates, wax, vape cartridges)
  • Smoked route vs. ingested
  • Concurrent tobacco, cocaine, or stimulant use
  • Elderly patients - also at risk for orthostatic hypotension post-use
  • Dose and frequency - heavy/daily use carries the highest risk

Management

There is no standardized cannabis-specific MI protocol. Management follows standard ACS guidelines:
  1. STEMI/NSTEMI pathway as appropriate - primary PCI for STEMI
  2. Antiplatelet therapy (aspirin + P2Y12 inhibitor)
  3. Anticoagulation per standard ACS protocol
  4. Beta-blockers - used with caution; they block the beta-mediated tachycardia but may unmask alpha-mediated coronary vasoconstriction, potentially worsening vasospasm
  5. Calcium channel blockers / nitrates - may be preferable when vasospasm is suspected (non-obstructive angiography)
  6. Supportive care: monitor for arrhythmias, hypotension (orthostatic hypotension is common post-intoxication)
  7. Cessation counseling - mandatory; recurrence risk remains if cannabis use continues
  8. Toxicology workup - rule out concurrent stimulants (cocaine, methamphetamine)

An Important Note on the Evidence

Robbins & Kumar Basic Pathology notes: "There is no strong evidence linking cannabis use to myocardial infarction or stroke" - this reflects the older textbook's position, which is now contradicted by more recent high-quality evidence. Multiple recent systematic reviews and meta-analyses (2022-2025) do find a statistically significant association. The causal link is biologically plausible and supported by the temporal pattern of events.

Key References

  • Storck W et al. (2025). Cardiovascular risk associated with the use of cannabis and cannabinoids: a systematic review and meta-analysis. Heart. [PMID 40527600]
  • van Amsterdam J & van den Brink W (2024). Cannabis Use Variations and Myocardial Infarction: A Systematic Review. J Clin Med. [PMID 39337107]
  • Yang PK et al. (2022). Nonmedical Marijuana Use and Cardiovascular Events: A Systematic Review. Public Health Rep. [PMID 33636088]
  • Murray & Nadel's Textbook of Respiratory Medicine - Cardiovascular Toxicity of Cannabis
  • ACC.25 (2025) - Risk of MI in Cannabis Users meta-analysis
This is a shared conversation. Sign in to Orris to start your own chat.